Novel Treatment Strategies Utilizing Immune Reactions against Chronic Myelogenous Leukemia Stem Cells
Introduction of tyrosine kinase inhibitors (TKIs) has improved the prognosis of patients with chronic myelogenous leukemia (CML), and treatment-free remission (TFR) is now a treatment goal. However, about half of the patients experience molecular relapse after cessation of TKIs, suggesting that leuk...
Enregistré dans:
Auteur principal: | Maiko Matsushita |
---|---|
Format: | article |
Langue: | EN |
Publié: |
MDPI AG
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/d155489c7fbd45afb4e1e6b21cb70aad |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib
par: Emole J, et autres
Publié: (2016) -
JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia
par: Haidée Aranda-Tavío, et autres
Publié: (2021) -
Isolation of Mycobacterium branderi, an unusual species from an acute myelogenous leukemia patient
par: Majid Marjani, et autres
Publié: (2014) -
Atypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment Approaches
par: Panagiotis T. Diamantopoulos, et autres
Publié: (2021) -
Assessment of Oral Chemotherapy Nonadherence in Chronic Myeloid Leukemia Patients Using Brief Measures in Community Cancer Clinics: A Pilot Study
par: Terry C. Davis, et autres
Publié: (2021)